FGFR1 inhibitor-11_product_DataBase

Bioactivity	FGFR1 inhibitor-11 (compound 5g) binds to FGFR1, inactivation of its downstream ERK1/2 and IκBα/NF-κB signaling inhibited RANKL-induced osteoclastogenesis. FGFR1 inhibitor-11 has oral bioactivity[1].
Invitro	FGFR1 inhibitor-11 (compound 5g) (0-20μM，4 天) 可减弱骨髓来源巨噬细胞中 RANKL 诱导的破骨细胞生成[1]。FGFR1 inhibitor-11 (0-160 μM; 48 h) 在低于 20 μM 的 BMDM 中没有表现出明显的毒性[1]。FGFR1 inhibitor-11 (0-10 μM) 抑制 F-肌动蛋白带的形成[1]。FGFR1 inhibitor-11 (0-10 μM) 通过减少 NFATc1 和 c-fos 来抑制破骨细胞生成所需基因的表达，从而抑制破骨细胞生成[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> FGFR1 inhibitor-11 相关抗体: Cell Viability Assay[1] Cell Line:
In Vivo	FGFR1 inhibitor-11 (15-30 mg/kg; 口服；每天 2 次）可显着预防小鼠骨质流失 (BV、T-BMD 等)[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only.
CAS	2157482-40-9
Formula	C23H18O4
Molar Mass	358.39
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Zhihao Chen, et al. Discovery of a novel homoisoflavonoid derivative 5g for anti-osteoclastic bone loss via targeting FGFR1. Eur J Med Chem. 2024 Mar 27:270:116335.

PeptideDB